NASDAQ: CARLCarlsmed Inc Stock
$12.57-0.97 (-7.16%)
Updated Jan 16, 2026
CARL Price
$12.57
Fair Value Price
N/A
Market Cap
$334.27M
52 Week Low
$11.45
52 Week High
$17.19
P/E
N/A
P/B
3.13x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.26
Operating Cash Flow
N/A
Beta
1.49
Next Earnings
Feb 19, 2026
Ex-Dividend
N/A
Next Dividend
N/A
CARL Overview
Carlsmed, Inc. develops and operates a surgical platform for the treatment of complex adult spinal deformities that enables surgeons to harness clinical intelligence, advanced image recognition, and 3D printing technologies. Its product includes aprevo, a medical platform that makes surgical plans and devices tailored to the precise medical situation of every individual patient. It provides New Technology Add-On Payment (NTAP) reimbursement. The company was incorporated in 2018 and is based in Carlsbad, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CARL's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Health Information Service
Industry Rating
B
CARL
Ranked#39 of 45
Ranked#39 of 45
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $152.77 | A | |
| $12.15 | A | |
| $2.90 | A |
Be the first to know about important CARL news, forecast changes, insider trades & much more!
CARL News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CARL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CARL is good value based on its book value relative to its share price (3.13x), compared to the US Health Information Services industry average (3.84x)
P/B vs Industry Valuation
CARL's short-term assets ($131.47M) exceed its short-term liabilities ($10.93M)
Short-term Liabilities Financials
CARL's short-term assets ($131.47M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
There are 30 more CARL due diligence checks available for Premium users.
Valuation
CARL price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.13x
Industry
3.84x
CARL is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CARL's financial health
Profit margin
Revenue
$13.1M
Net Income
-$8.5M
Profit Margin
-65.2%
Assets to liabilities
Assets
$134.9M
Liabilities
$28.2M
Debt to equity
0.26
CARL's short-term assets ($131.47M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CARL's short-term assets ($131.47M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CARL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$8.5M
Investing
-$343.0k
Financing
$90.7M
CARL vs Health Information Service Stocks
Carlsmed Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.